Theolytics Ltd.

The funding will support Theolytics’ Phase 1 clinical trial for THEO-260 in ovarian cancer and incorporates comprehensive biomarker studies to showcase the candidate's differentiated dual tumour-lytic and immunotherapeutic mechanism of action Oxford UK September 2nd, 2024. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic viral therapies, has been awarded £2M from Innovate UK’s prestigious Transforming Cancer Therapeutics grant funding competition to support the clinical development of its lead candidate THEO-260. This non-dilutive funding adds to the £19M raised earlier this year from a strong investor syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, Sound Bioventures and Oxford University Innovation. Innovate UK, part of UK Research and Innovation, invests in innovative projects that are positioned to advance next-generation immunotherapies for cancer. The grant will primarily support the Company’s upcoming Phase 1 multi-centre, open-label first-in-human trial to evaluate safety and tolerability of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer and determine the recommended Phase 2 dose. This trial is expected to begin in the coming months. It will further allow for comprehensive analysis to elucidate and evidence THEO-260’s unique dual mechanism of action to destroy immune suppressive stromal cells and induce T cell activation through a comprehensive biomarker study, including the development of novel biomarker tests. Proceeds will also support the evolution of Theolytics as it continues to expand its footprint and reach as a clinical-stage oncology biotech company. “This competitive award from Innovate UK in the category of “Transforming Cancer Therapeutics” reflects the novelty of our research as well as our ability to deliver operational excellence as we move forward to the clinic. This will allow us to precisely demonstrate the mechanism of action of THEO-260, which we anticipate will provide key information to enhance further development of this immunotherapeutic oncolytic virus and our wider platform," said Miriam Bazan Peregrino, Theolytics’ VP Translational Development. CSO and Co-Founder Margaret Duffy shared; “We are excited to be edging closer to providing a treatment option for women with Ovarian Cancer. This is a devastating disease for which current treatment options are limited. We are grateful for the support of Innovate UK in partnering with us to help achieve our aim to transform the lives of cancer patients.” THEO-260 is a next-generation oncolytic adenovirus for the treatment of ovarian cancer. Positioned to tackle the complex, immune suppressed nature of advanced solid tumours. It demonstrates effective killing of cancer cells and cancer-associated fibroblasts (CAFs), whilst inducing immune activation in advanced preclinical models, including extensive panels of ovarian cancer patient samplesTHEO-260 will be evaluated in Phase I clinical trials by intravenous and intraperitoneal delivery to ovarian cancer patients. Theolytics is working to develop best-in-class oncolytic viral therapies. The company has pioneered a new approach to develop efficacious, targeted candidates suitable for systemic intravenous delivery. The company is focused on the advancement of its lead program THEO-260 into the clinic with the ambition of providing better outcomes for patients with ovarian cancer, for whom current treatment options are limited. Additional pipeline programmes in preclinical development include novel candidates developed for colorectal cancer and hematological malignancies where there remains significant unmet need. Theolytics, which was founded in 2017 and is headquartered in Oxford, UK, is backed by international life sciences investors Taiho Ventures, M Ventures, Oxford Science Enterprises, Epidarex Capital, Sound Bioventures and Oxford University Innovation. Innovate UK, part of UK Research and Innovation (UKRI), is the UK’s innovation agency. It works to create a better future by inspiring, involving and investing in businesses developing life-changing innovations. Its mission is to help companies to grow through their development and commercialisation of new products, processes and services, supported by an outstanding innovation ecosystem that is agile, inclusive and easy to navigate. The content above comes from the network. if any infringement, please contact us to modify.

OXFORD, England, July 12, 2024 /PRNewswire/ -- Today Theolytics, a clinical stage biotechnology company harnessing viruses to combat disease, announced that Charlotte Casebourne Stock, Co-Founder and CEO, has decided to transition into an advisory role with the company. Mike Grey, Executive Chair of the board of directors will assume overall leadership responsibility until further notice. Continue Reading Charlotte Casebourne Stock moves on from Theolytics to next entrepreneurial endeavour Charlotte Casebourne Stock shares: "It's been extremely rewarding leading Theolytics from idea at inception in 2017 to dosing the first ovarian cancer patient with our lead oncolytic virus candidate THEO-260 this year. I set out on my entrepreneurial journey to drive equitable access to healthcare innovation, and to create sustainable companies. With the progress made, and our investors' support for Theolytics' lead clinical program, it is the right time for me to embark on a new chapter, in line with my personal mission." Mike Grey commented: "On behalf of the board and Theolytics' investors we would like to extend our heartfelt appreciation to Charlotte. Without her, Theolytics wouldn't be in the strong position the company finds itself in today. Under Charlotte's leadership, over $40m of dilutive and non-dilutive capital was raised, and in only seven years the company has advanced into the clinic. We respect her decision to pursue new entrepreneurial endeavors, and wish her the very best. I look forward to working with her as an advisor, alongside Theolytics' Board and team to execute on the promising strategy defined." About Theolytics Theolytics is working to develop next generation oncolytic viral therapies, pioneering a new approach to develop efficacious, targeted candidates suitable for systemic intravenous delivery. The company is focused on the clinical development of its lead program, with the ambition of providing better outcomes for patients with ovarian cancer. Theolytics is backed by international life sciences investors M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, Sound Bioventures and The University of Oxford. Photo - CONTACT: [email protected] SOURCE Theolytics

April 17th, 2024. Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a total of £19M ($24.5M) with the addition of Sound Bioventures as a new investor. Sound Bioventures joins a strong international syndicate of existing investors participating in the round that includes M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford. The proceeds from this financing round further strengthen the company’s position as it advances its lead oncolytic adenovirus - THEO-260 - into clinical trials in ovarian cancer. The first trials are planned for this year and will aim to demonstrate safe, effective administration, and provide insight to the candidate’s dual cancer/cancer-associated fibroblast-killing and immunomodulatory mechanism of action when administered by intravenous or intraperitoneal routes in platinum-resistant ovarian cancer patients. Following this investment, Thomas Tan, Principal at Sound Bioventures, will join Theolytics’ Board of Directors. Charlotte Casebourne Stock, Chief Executive Officer of Theolytics, said; “We're on the brink of a potential step-change for the oncolytic adenovirus field. Our lead asset THEO-260 will be entering the clinic this year, and at this key juncture we are pleased to complete this significant financing and welcome Sound Bioventures as a new investor alongside our existing investors. Sound Bioventures’ extensive oncology experience, network, operational expertise and collaborative approach will bring important benefits to Theolytics and I am delighted to welcome Thomas Tan to our Board.” Thomas Tan, Principal at Sound Bioventures, added; “The oncolytic virus modality is rapidly evolving, and we believe that Theolytics is well positioned at the forefront of this exciting therapy area. With THEO-260 about to enter the clinic, we see a significant opportunity to help bring an important and potentially practice-changing therapy to the many women suffering from this fatal disease. I look forward to working with the Board and management team bringing our hands-on approach to support the company’s unwavering fight against cancer.” “THEO-260 has the potential to bring a much-needed new therapy to ovarian cancer patients and their families that are impacted by this devastating disease,” said Mike Grey, Executive Chair of the Board. “Theolytics is at a pivotal point as it approaches its first clinical trial and we are delighted to welcome Sound Bioventures, a highly knowledgeable and experienced investor with extensive oncology and company building expertise, to our group of leading international investors.” It is estimated that around 7,500 women in the UK and 20,000 women in the US will be diagnosed with ovarian cancer in 2024. More than 75% of cases will be diagnosed at an advanced stage (grade-III/IV) with less than 25% of patients expected to survive for more than five years. Standard-of-care, first-line treatments combine cytoreductive-surgery, platinum-based chemotherapies, and paclitaxel. Although initially effective, more than 70% of patients relapse within three years and become resistant to platinum-based therapies. There are no effective treatments for platinum-resistant OC and at this point patients have a life-expectancy of less than 12 months. THEO-260 is a next-generation oncolytic adenovirus for the treatment of (platinum-resistant) ovarian cancer. It is highly efficacious in killing cancer cells and cancer-associated fibroblasts in ovarian cancer patient tumour samples. The destruction of cancer-associated fibroblasts, in addition to cancer cells, is a potentially differentiating feature of THEO-260 as cancer-associated fibroblasts in stromal-rich tumours are a barrier to the effectiveness of many cancer treatments. THEO-260 is being explored as a therapeutic for intravenous and intraperitoneal delivery. Theolytics is working to develop next-generation oncolytic viral therapies. The company has pioneered a new approach to develop efficacious, targeted candidates suitable for systemic intravenous delivery. The company is focused on the advancement of its lead program THEO-260 into the clinic with the ambition of providing better outcomes for patients with ovarian cancer, for whom current treatment options are limited. Additional pipeline programmes in preclinical development include novel candidates developed for colorectal cancer and hematological malignancies where there remains significant unmet need. Theolytics, which was founded in 2017 and is headquartered in Oxford, UK, is backed by international life sciences investors M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, Sound Bioventures and the University of Oxford. The content above comes from the network. if any infringement, please contact us to modify.